Clinical Trials/NCT02136316

NCT02136316

Completed

Phase 1

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Oral Multiple Doses of ASP7962 in Healthy Male and Female Subjects

Astellas Pharma Europe B.V.1 site in 1 country48 target enrollmentMay 2014

ConditionsHealthy Volunteers Pharmacokinetics of ASP7962

InterventionsASP7962 Placebo

DrugsASP7962 Placebo

Overview

Phase: Phase 1
Intervention: ASP7962
Conditions: Healthy Volunteers
Sponsor: Astellas Pharma Europe B.V.
Enrollment: 48
Locations: 1
Primary Endpoint: Safety as assessed by adverse events
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and tolerability as well as the pharmacokinetics of increasing oral multiple doses of ASP7962 in healthy young male and female subjects.

Detailed Description

Subjects will be admitted to the clinical unit and will stay residential for a total of 20 days/19 nights, to be discharged from the clinical unit on day 19.

Registry

clinicaltrials.gov

Start Date

May 2014

End Date

November 2015

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Astellas Pharma Europe B.V.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject has a body mass index of 18.5 - 30.0 kg/m2, inclusive. Subject weighs at least 50 kg.
•Female subject must be of non-childbearing potential:
•Postmenopausal (defined as at least 1 year without any menses and confirmation of FSH levels) prior to screening, or
•Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening).
•Male subject and their female spouse/partner who are of childbearing potential must be using 2 highly effective forms of birth control (1 of which must be a barrier method) starting at screening and continued throughout the clinical study period, and for 90 days after the final study drug administration.
•Male subject must not donate sperm starting at screening, throughout the clinical study period, and for 90 days after the final study drug administration.
•Subject agrees not to participate in another interventional study while participating in the present clinical study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria

•Subject has a known or suspected hypersensitivity to ASP7962 or any components of the formulation used.
•Subject has a history of suicide attempt or suicidal behavior. Any suicidal ideation within the last 3 months.
•Subject has any of the liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase, gamma glutamyl transferase, total bilirubin \[TBL\]) above the upper limit of normal \[ULN\]. In such a case the assessment may be repeated once \[day -1\].
•Subject has any clinically significant history of allergic conditions.
•Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to admission to the clinical unit on day -
•Subject has a mean pulse rate \< 40 or \> 90 bpm; mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DPB) \> 90 mmHg (vital sign measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse rate will be measured automatically) \[day -1\]. If the mean pulse rate, mean SBP or mean DBP is out of the range as specified above, 1 additional triplicate measurement may be taken on day -
•Subject has a mean corrected QT interval using Fridericia's formula (QTcF) interval \> 430 ms (for male subjects) and \> 450 ms (for female subjects) on admission to the clinical unit on day
•If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken \[day -1\].
•Subject uses any prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day).
•Subject has used nicotine-containing products within 6 months prior to admission to the clinical unit.

Arms & Interventions

ASP7962 low dose

Intervention: ASP7962

ASP7962 medium dose

Intervention: ASP7962

ASP7962 high dose

Intervention: ASP7962

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Safety as assessed by adverse events

Time Frame: up to end of study visit (29 days)

Safety as assessed by vital signs

Time Frame: up to end of study visit (29 days)

Safety as assessed by CogState cognitive test battery: Groton Maze Learning Task, Groton Maze Learning Task-Delayed Recall, Detection Task, Identification Task, One Card Learning Task, One Back Task

Time Frame: Day 3-19

Safety as assessed by orthostatic challenge test

Time Frame: Day 1 and 16

Safety as assessed by clinical laboratory tests

Time Frame: up to end of study visit (29 days)

Safety as assessed by electrocardiogram (ECG)

Time Frame: up to end of study visit (29 days)

Routine 12-lead ECG, continuous cardiac monitoring (Holter ECG) and real-time cardiac monitoring (ECG telemetry)

Safety as assessed by Bond and Lader visual analogue scale (VAS)

Time Frame: Day 3-19

Safety as assessed by Addiction Research Center Inventory (ARCI)-49 (49-item)

Time Frame: Day 3-19

Safety as assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)

Time Frame: Day 2-19

Secondary Outcomes

Pharmacokinetic profile of ASP7962 (plasma): AUC12, AUC12,u, AUCinf, AUCinf,u , AUClast, AUClast,u, CL/F, CLu/F, Cmax(up to Day 19)
Pharmacokinetic profile of ASP7962 (plasma): Ctrough, AUCtau, Rac(AUC), Rac(Cmax), PTR, Ratio AUCu/AUC, Vz,u/F, AUCtau,u(up to Day 19)
Pharmacokinetic profile of ASP7962 (plasma): Cmax,u, MRT, t1/2, tmax, tlag, λz, fu, AUCinf,u/AUCinf , Vz/F(up to Day 19)
Pharmacokinetic profile of ASP7962 (urine): Aeinf, Aeinf%, Aelast, Aelast%, CLR, CLR,u, Aetau, Aetau%(Day 1 and 16)